{
  "patent_number": "US 12600775",
  "country": "US",
  "title": "Treating a Specific Lymphoma with Modified T Cells",
  "original_title": "Chimeric antigen receptor T cell therapy",
  "summary": "This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.",
  "what_it_does": "This patent outlines a method for treating relapsed or refractory mantle cell lymphoma (MCL) in patients who have specific tumor characteristics, either a Ki-67 tumor proliferation index of 50% or higher, or a TP53 gene mutation (Claim 1). The treatment involves collecting a patient's own (autologous) T cells from their blood, enriching them for specific types (CD4+ and CD8+), and removing any circulating cancer cells (Claim 1). These T cells are then engineered to express a \"chimeric antigen receptor\" (CAR) that specifically targets a protein called CD19, using a particular anti-CD19 component called FMC63 (Claim 1). Before receiving these modified T cells, patients may get a \"bridging therapy\" and a \"lymphodepleting chemotherapy\" to prepare their body (Claims 5, 7).",
  "what_it_does_not_cover": [
    "Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (Claim 1).",
    "Does not cover CAR T cell therapies that use T cells from a donor (allogeneic) rather than the patient's own (autologous) cells (Claim 1).",
    "Does not cover CAR T cells designed to target cancer markers other than CD19, or those using a different anti-CD19 component than the FMC63 single-chain variable fragment (scFv) (Claim 1).",
    "Does not cover CAR T cells prepared without the specific steps of positive enrichment and partial or complete depletion of circulating cancer cells from peripheral blood mononuclear cells (Claim 1).",
    "Does not cover CAR T cells that use different intracellular signaling regions than the specified CD28 and CD3-zeta domains (Claim 1)."
  ],
  "filed": "2020-11-06",
  "granted": "2026-04-14",
  "expires": "2040-11-06",
  "status": "active",
  "holder": "Kite Pharma",
  "holder_url": "https://patentbrief.org/company/kite-pharma",
  "inventors": [
    {
      "name": "John Rossi",
      "url": "https://patentbrief.org/inventor/john-rossi"
    },
    {
      "name": "Adrian Bot",
      "url": "https://patentbrief.org/inventor/adrian-bot"
    }
  ],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "gene_editing",
    "immunotherapy"
  ],
  "abstract": "Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy.",
  "url": "https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy",
  "markdown_url": "https://patentbrief.org/patent/us/12600775/chimeric-antigen-receptor-t-cell-therapy/md",
  "google_patents_url": "https://patents.google.com/patent/US12600775",
  "relatedPatents": [
    {
      "patentNumber": "9328156",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Attack Cancer",
      "url": "https://patentbrief.org/patent/us/9328156/use-of-chimeric-antigen-receptor-modified-t-cells-to-treat-cancer"
    },
    {
      "patentNumber": "9481728",
      "countryCode": "US",
      "title": "How Genetically Modified T-Cells Fight CD19 Cancers",
      "url": "https://patentbrief.org/patent/us/9481728/compositions-and-methods-for-treatment-of-cancer"
    },
    {
      "patentNumber": "20240165159",
      "countryCode": "US",
      "title": "Targeting Cancer with CAR T Cells Using a Chemical Tag",
      "url": "https://patentbrief.org/patent/us/20240165159/compositions-and-methods-for-car-t-cell-therapy"
    },
    {
      "patentNumber": "20250171803",
      "countryCode": "US",
      "title": "Targeting Cancer with CAR T Cells Using Small Molecule 'Flags'",
      "url": "https://patentbrief.org/patent/us/20250171803/methods-and-compositions-for-car-t-cell-therapy"
    },
    {
      "patentNumber": "12163952",
      "countryCode": "US",
      "title": "Predicting and Treating Dangerous Side Effects in CAR T-Cell Therapy",
      "url": "https://patentbrief.org/patent/us/12163952/determining-toxicity-risk-in-car-t-cell-therapy"
    }
  ]
}